JP2013515071A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515071A5
JP2013515071A5 JP2012546122A JP2012546122A JP2013515071A5 JP 2013515071 A5 JP2013515071 A5 JP 2013515071A5 JP 2012546122 A JP2012546122 A JP 2012546122A JP 2012546122 A JP2012546122 A JP 2012546122A JP 2013515071 A5 JP2013515071 A5 JP 2013515071A5
Authority
JP
Japan
Prior art keywords
formulation
antibody
concentration
buffer
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012546122A
Other languages
English (en)
Japanese (ja)
Other versions
JP6214161B2 (ja
JP2013515071A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/061347 external-priority patent/WO2011084750A1/en
Publication of JP2013515071A publication Critical patent/JP2013515071A/ja
Publication of JP2013515071A5 publication Critical patent/JP2013515071A5/ja
Application granted granted Critical
Publication of JP6214161B2 publication Critical patent/JP6214161B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012546122A 2009-12-21 2010-12-20 抗体製剤 Active JP6214161B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28853509P 2009-12-21 2009-12-21
US61/288,535 2009-12-21
PCT/US2010/061347 WO2011084750A1 (en) 2009-12-21 2010-12-20 Antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015135000A Division JP6527038B2 (ja) 2009-12-21 2015-07-06 抗体製剤

Publications (3)

Publication Number Publication Date
JP2013515071A JP2013515071A (ja) 2013-05-02
JP2013515071A5 true JP2013515071A5 (OSRAM) 2014-02-13
JP6214161B2 JP6214161B2 (ja) 2017-10-18

Family

ID=43733329

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012546122A Active JP6214161B2 (ja) 2009-12-21 2010-12-20 抗体製剤
JP2015135000A Active JP6527038B2 (ja) 2009-12-21 2015-07-06 抗体製剤
JP2017177621A Pending JP2018035170A (ja) 2009-12-21 2017-09-15 抗体製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015135000A Active JP6527038B2 (ja) 2009-12-21 2015-07-06 抗体製剤
JP2017177621A Pending JP2018035170A (ja) 2009-12-21 2017-09-15 抗体製剤

Country Status (19)

Country Link
US (5) US20110226650A1 (OSRAM)
EP (2) EP2515941B1 (OSRAM)
JP (3) JP6214161B2 (OSRAM)
KR (3) KR101989628B1 (OSRAM)
CN (2) CN107095846A (OSRAM)
AR (1) AR079556A1 (OSRAM)
AU (1) AU2010339770B2 (OSRAM)
BR (1) BR112012013093A2 (OSRAM)
CA (1) CA2783846C (OSRAM)
ES (1) ES2765657T3 (OSRAM)
IL (1) IL219537B (OSRAM)
MX (2) MX2012006831A (OSRAM)
MY (1) MY159156A (OSRAM)
PL (1) PL2515941T3 (OSRAM)
RU (2) RU2609658C2 (OSRAM)
SG (3) SG181834A1 (OSRAM)
TW (2) TWI623323B (OSRAM)
WO (1) WO2011084750A1 (OSRAM)
ZA (1) ZA201203242B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2314315T3 (en) 1999-06-01 2015-02-02 Biogen Idec Inc Blocking monoclonal antibody to the human alpha1-I domain of VLA-1 and their use for the treatment of inflammatory diseases
NZ529494A (en) 2001-04-13 2005-08-26 Biogen Idec Inc Antibodies to VLA-1
EP2839843B1 (en) 2006-05-25 2018-06-20 Biogen MA Inc. VLA-1 antagonist for use in treating stroke
CN107095846A (zh) * 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
US20140044727A1 (en) * 2011-04-07 2014-02-13 Glaxosmithkline Llc Formulations with reduced viscosity
WO2013040196A2 (en) 2011-09-14 2013-03-21 Immunovative Therapies, Ltd. Automated device for biologic drug distribution
US9642918B2 (en) * 2011-12-16 2017-05-09 Pfizer Inc. Combination of inotuzumab ozogamicin and torisel for the treatment of cancer
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
AU2013265255B2 (en) * 2012-05-25 2018-03-29 Novartis Ag Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition
TWI610861B (zh) * 2012-09-13 2018-01-11 梵提夫免疫療法公司 用於生物藥品分配的自動化裝置
US20150250879A1 (en) * 2012-09-27 2015-09-10 Octapharma Ag Test for hemolytic potential of pharmaceutical products and formulations for risk minimization
NZ711567A (en) * 2013-03-13 2020-04-24 Genentech Inc Antibody formulations
CN103385852B (zh) * 2013-08-06 2015-03-11 南京正大天晴制药有限公司 一种盐酸法舒地尔注射液及其制备方法
WO2015071348A1 (en) * 2013-11-18 2015-05-21 Formycon Ag Pharmaceutical composition of an anti-vegf antibody
WO2015134406A1 (en) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
CN104906576B (zh) * 2014-03-13 2018-06-19 四川科伦博泰生物医药股份有限公司 可供皮下注射的高浓度抗vegf抗体配制剂
EP3193932B1 (en) 2014-09-15 2023-04-26 F. Hoffmann-La Roche AG Antibody formulations
TWI738632B (zh) 2014-11-07 2021-09-11 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
CN104922668B (zh) * 2014-12-10 2019-08-23 信达生物制药(苏州)有限公司 一种稳定的抗vegf抗体制剂及其用途
MX2017009759A (es) 2015-01-28 2017-10-27 Pfizer Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
CN107537036A (zh) * 2016-06-27 2018-01-05 江苏泰康生物医药有限公司 一种抗人血管内皮生长因子单克隆抗体的药物制剂及其应用
US11692027B2 (en) 2016-09-28 2023-07-04 Board Of Regents, The University Of Texas System Antibody and protein therapeutic formulations and uses thereof
CN106918658B (zh) * 2017-01-22 2020-01-31 合肥拓锐生物科技有限公司 一种阿昔替尼原料及其制剂中有关物质的分析方法
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
JOP20200215A1 (ar) 2018-03-05 2020-09-03 Janssen Pharmaceutica Nv الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
CA3150482A1 (en) 2019-09-16 2021-03-25 Amgen Inc. Method for external sterilization of drug delivery device
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂
TW202128220A (zh) * 2019-10-08 2021-08-01 韓商三星Bioepis股份有限公司 穩定液體組合物、其製備方法及含有其之調配物
WO2021079337A1 (en) * 2019-10-23 2021-04-29 Cadila Healthcare Limited Pharmaceutical formulation of anti-her2 antibody and preparation thereof
MX2023000695A (es) * 2020-07-14 2023-04-20 Janssen Pharmaceutica Nv Ensayo basado en sangre para la detección de tauopatía o enfermedad amiloidogénica.
AU2021367878A1 (en) * 2020-10-26 2023-06-22 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
WO2025101487A1 (en) * 2023-11-06 2025-05-15 Bruker Cellular Analysis, Inc. Affinity assay for microfluidic devices

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク,インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン コーポレーション Hiv感染治療のための異種複合抗体
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
AU729039C (en) 1996-08-30 2001-08-02 Upfront Chromatography A/S Isolation of immunoglobulins
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
WO1999048527A1 (en) * 1998-03-27 1999-09-30 Genentech, Inc. Apo-2 ligand-anti-her-2 antibody synergism
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
DE60039596D1 (de) 1999-03-30 2008-09-04 Japan Tobacco Inc Verfahren zur herstellung von monoklonalen antikörpern
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1222292B1 (en) 1999-10-04 2005-08-31 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
JP2005519580A (ja) 2001-05-16 2005-07-07 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ 非ヒト動物由来のヒト抗肺炎球菌抗体
EP1425389B1 (en) 2001-08-23 2011-11-02 Genmab A/S Human antibodies specific for interleukin 15 (il-15)
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
JP2007525410A (ja) 2003-01-17 2007-09-06 ザ リサーチ ファンデーション オブ ステイト ユニバーシティ オブ ニューヨーク 膵臓癌に関連する抗原、それらに対する抗体、及び診断方法及び処置方法
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
AR044302A1 (es) 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
CA2526398C (en) 2003-05-21 2014-07-15 Medarex, Inc. Human monoclonal antibodies against bacillus anthracis protective antigen
PL1638941T3 (pl) 2003-05-22 2010-11-30 Abbvie Bahamas Ltd Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
BRPI0417406A (pt) 2003-12-08 2007-04-03 Immunogen Inc anticorpo do receptor anti-igf-i
JP5599136B2 (ja) * 2004-04-14 2014-10-01 ジェネンテック, インコーポレイテッド 血管の発達を調節するための、egfl7アンタゴニストを含む組成物
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CN101426527A (zh) * 2006-02-03 2009-05-06 米迪缪尼有限公司 蛋白质制剂
BRPI0710826A2 (pt) * 2006-04-21 2011-08-23 Novartis Ag composições farmacêuticas de anticorpo anti-cd40 antagonista
CA2654584A1 (en) * 2006-06-05 2007-12-21 Genentech, Inc. Extending survival of cancer patients with elevated levels of egf or tgf-alpha
WO2008150305A1 (en) * 2007-06-07 2008-12-11 Nastech Pharmaceutical Company Inc. Intranasal carbetocin formulations and methods for the treatment of autism
CA2692165A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
US20100189721A1 (en) * 2007-07-06 2010-07-29 Smithkline Beecham Corporation Antibody formulations
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
CN107095846A (zh) * 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂

Similar Documents

Publication Publication Date Title
JP2013515071A5 (OSRAM)
RU2017102553A (ru) Состав, содержащий антитело
US12012448B2 (en) High concentration anti-C5 antibody formulations
EP3310809B1 (en) Anti-cgrp antibody formulation
JP2016515124A5 (OSRAM)
JP2008520551A5 (OSRAM)
AU2014291970B2 (en) Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
JP2020516608A (ja) 安定な抗体製剤
US20240000934A1 (en) Antibody Compositions and Methods of Use Thereof
JP2017528480A5 (OSRAM)
RU2015143607A (ru) Составы антител
JP2015519382A5 (OSRAM)
CA3181026A1 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
US20240052026A1 (en) Stable antibody formulation, preparation method therefor, and applications thereof
WO2022017468A1 (zh) Pd-l1/lag-3双特异性抗体制剂及其制备方法和用途
WO2016045570A2 (zh) 一种针对血管内皮生长因子的人源化抗体的药物组合物
JP2024522620A (ja) アトピー性皮膚炎及び関連する障害の治療方法
TW202124454A (zh) 抗pcsk9抗體用於預防或治療膽固醇相關疾病的方法
CN109843266A (zh) 稳定的布洛芬注射组合物
HK40075622A (en) Stable antibody preparation, and preparation method and use thereof
JP2024522165A (ja) 2019新型コロナウイルス抗体含有医薬製剤
HK40025392B (en) High concentration anti-c5 antibody formulations
BR122023005826B1 (pt) Solução aquosa estável compreendendo um anticorpo anti-c5, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma